Trovagene

TROV NASDAQ
3.120
+0.020
+0.65%
盘后: 3.120 0 0.00% 17:10 05/23 EDT
开盘
3.200
昨收
3.100
最高
3.200
最低
3.020
成交量
36.29万
成交均量(3M)
119.07万
52周最高
20.26
52周最低
2.536
换手率
6.95%
市值
1,630.16万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Trovagene TROV股票价格,Trovagene股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
展开 >

最近浏览

名称
价格
涨跌幅